Primary Care POC Diagnostics Market Size & Share 2024 –2032

Primary Care POC Diagnostics Market Size

Primary Care POC Diagnostics Market size was valued at USD 18.3 billion in 2023 and is estimated to expand at 7% CAGR from 2024 to 2032. Point-of-care (POC) diagnostics in primary care refer to medical tests or diagnostic procedures that are performed at or near the location wherein patient care is provided, typically in a primary care setting such as a doctor's office, clinic, or community health center.

The primary goal of POC diagnostics is to obtain rapid and accurate diagnostic information, enabling healthcare providers to make immediate decisions about patient care. The increasing incidence of infectious diseases and chronic conditions including cardiovascular diseases is one of the major factors driving the demand for primary care POC diagnostics market progress. For instance, according to the World Health Organization (WHO) report, in 2021, there were around 37.7 million individuals suffering with human immunodeficiency virus (HIV).
 

Furthermore, the growing prevalence of diabetes worldwide is a significant factor contributing to increasing point of care testing, which is estimated to account for over USD 78 billion by 2032, at home-care settings. Additionally, as per statistics, approximately 537 million adults were individuals suffering from diabetes in 2021. Diabetic foot ulcers and pressure ulcers are a common complication and are a major cause of hospital admissions in people with diabetes. Thus, this growing prevalence of diabetes is anticipated to boost demand of primary care POC diagnostics and thereby accelerate market expansion.
 

Primary Care POC Diagnostics Market Trends

The increasing technological advancements in the primary care POC diagnostics market is projected to augment significant industry expansion. Current trend in the industry is strongly persuaded towards smart devices equipped with mobile healthcare that will significantly accelerate growth of remote patient monitoring and management. Wide range of mobile healthcare technologies have been developed, of which cell phone-based point of care technologies has become the most prominent technology.  
 

• In addition, real time PCR has significantly expanded diagnostic capability through its capability of amplification and pathogen DNA identification technology
   
• Thus, high accuracy levels, more reliability as well as rapid and precise results delivered by numerous molecular tests has stimulated its demand in infectious disease management, thereby escalating the market growth.
   
• Moreover, growing government initiatives towards acute cases including road traffic accidents, developing healthcare infrastructure, and patient support programs will spur the adoption of primary care POC diagnostics, thus propelling market revenue growth.
   

Primary Care POC Diagnostics Market Analysis

The primary care POC diagnostics market by product is categorized into glucose monitoring, cardiometabolic testing products, infectious disease testing products, coagulation testing products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drug-of-abuse (DoA) testing products, fecal occult testing products, and other products. The glucose monitoring segment garnered USD 4.5 billion revenue size in the year 2023.
 

• High segment growth is attributed to the increasing adoption of portable, highly convenient, and cost-effective as well as rapid primary POC glucose tests. Furthermore, the advantage of point of care testing for blood glucose (BG) is its rapid turn-around time as compared to central laboratory testing (CLT). For instance, the turn-around time for blood glucose point of care testing (POCT) is 5 minutes while that of CLT is between 30-60 minutes.
   
• Moreover, the postanalytical and preanalytical factors such as transportation, multiple user handling, order verification and delayed reporting can affect the analysis of test. Thus, aforementioned factors are eliminated in the primary care blood glucose POCT, thereby supplementing the market demand.

Learn more about the key segments shaping this market

Download Free PDF

Based on end-use, the primary care POC diagnostics market is segmented into hospitals, diagnostic centers, research laboratories, home care settings, and other end-users. The hospitals segment garnered USD 6.5 billion revenue size in the year 2023.
 

• Hospitals have primary care POC diagnostics teams and specialized primary care POC diagnostics nurses that are experienced in assessing, treating, and managing various types of diseases. They are knowledgeable about the latest primary care POC diagnostics techniques and technologies.
   
• Further, due to high incidence and prevalence of chronic diseases, there is a huge surge in number of patients getting hospitalized. The POC tests are much convenient for constant monitoring of specific analyte or repeated/ routine follow-up tests for tracking the treatment progress.
   
• Moreover, the primary care point of care tests reduces turnaround time drastically, which is essential and very effective in managing complicated cases in particular cardiovascular disease. The use of primary care POCT systems uplift the status of healthcare in hospitals, thereby fostering the industry landscape.

U.S. primary care POC diagnostics market accounted for USD 6.9 billion revenue size in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• Increasing government initiatives towards chronic and infectious diseases will accelerate industry expansion.
   
• For instance, National Diabetes Education Program (NDEP) is the joint effort of the National Institutes of Health and Centers for Disease Control and Prevention (CDC). National Diabetes Education Program seeks at reducing burden of prediabetes by delivering diabetes-related education to a range of people of emerging nations, faith-based organizations, ethnic minorities, community-based organizations, and healthcare providers.
   
• Furthermore, the strong focus on research and development and continuous innovation in primary care POC diagnostics will bolster the market demand.
   

Primary Care POC Diagnostics Market Share

The primary care POC diagnostics industry is consolidated, with key players including, Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories, and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market share.
 

For instance, in October 2021, Bio-Rad Laboratories launched new CFX Opus 96 Dx System and the CFX Opus 384 Dx System, real-time PCR detection systems. This system offers precise quantification to improve assay development, workflow efficiencies and productivity for diagnostic testing and research. This strategy improved diagnostic test outcomes and enabled in augmenting revenue growth.
 

Primary Care POC Diagnostics Market Companies

Some of the eminent market participants operating in the primary care POC diagnostics industry include:

• Abbott Laboratories
• ACON Laboratories, Inc.
• Becton, Dickinson, and Company
• BioMerieux SA
• Bio-Rad Laboratories, Inc
• Dexcom, Inc.
• Dragerwerk Ag & Co.
• F. Hoffmann-La Roche
• HemoCue AB (Danaher Corporation)
• Nova Biomedical
• Siemens Healthineers AG
• Sysmex Corporation
   

Primary Care POC Diagnostics Industry News:

• In January 2022, Roche launched the cobas pulse system in selected countries across Europe. The cobas pulse system is an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care. This strategy enabled the company to expand its geographic presence as well as enhance its product offerings by including digitally-enabled blood glucose monitoring devices.
   
• In May 2022, OraSure Technologies, Inc announced the selection of its InteliSwab COVID-19 Rapid Test by the U.S. Department of Health and Human Services (HHS) to be distributed to schools nationwide. This strategy helped the company to maintain its brand image and enhance its market presence.
   

Primary care POC diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product, 2018 – 2032 (USD Million)

• Glucose monitoring
• Cardiometabolic testing products
  • Cardiac marker testing products
    • hsTnl
    • BNP
    • D-dimer
    • CK-MB
    • Myoglobin
    • Other cardiometabolic testing products
  • Blood gas/electrolytes testing products
  • HBA1C testing products 
• Infectious disease testing products
  • Influenza testing products
  • HIV testing products
  • Hepatitis C testing products
  • Sexually transmitted disease (STD) testing products
  • Healthcare-associated infection (HAI) testing products
  • Respiratory infection testing products
  • Tropical disease testing products
  • Other infectious disease testing products
• Coagulation testing products
  • PT/INR testing products
  • Activated clotting time (ACT/APTT) testing products
• Pregnancy and fertility testing products
  • Pregnancy testing products
  • Fertility testing products
• Tumor/cancer marker testing products
• Cholesterol testing products
• Hematology testing products
• Drug-of-abuse (DoA) testing products
• Fecal occult testing products
• Urinalysis testing products
• Other products

By End-use, 2018 – 2032 (USD Million)

• Hospitals
• Diagnostic centers
• Research laboratories
• Home-care settings
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa